Prospecto: information for the user
Bridion 100mg/ml injectable solution
sugammadex
Read this prospect carefully before this medicine is administered to you,because it contains important information for you.
1.What Bridion is and for what it is used
2.What you need to know before starting Bridion administration
3.How Bridion is administered
4.Possible adverse effects
5.Storage of Bridion
6.Contents of the package and additional information
What is Bridion
Bridion contains the active ingredient sugammadex. Bridion is considered aSelective Muscle Relaxant Agentsince it only works with specific muscle relaxants, bromide of rocuronium or bromide of vecuronium.
How is Bridion used
If you need to undergo surgery, your muscles must be completely relaxed, which facilitates the surgeon's operation. To achieve this, during general anesthesia, they will administer medications to relax your muscles. These are calledmuscle relaxants, and examples include bromide of rocuronium and bromide of vecuronium. As these medications also block the muscles of respiration, you will need assistance with breathing (artificial respiration) during and after your operation until you can breathe on your own again.
Bridion is used to accelerate muscle recovery after surgery so that you can breathe on your own again sooner. It does this by combining with bromide of rocuronium or bromide of vecuronium in your body. It can be used in adults as long as bromide of rocuronium or bromide of vecuronium is used and in children and adolescents (between 2 and 17years), when bromide of rocuronium is used for moderate relaxation.
You should not receive Bridion
→ Inform your anesthesiologist if this is the case.
Warnings and precautions
Consult your anesthesiologist before startingthe administration of Bridion
Children and adolescents
This medication is not recommended for children under2years.
Other medications and Bridion
→ Inform your anesthesiologist if you are taking, have taken recently, or may need to take any other medication.
Bridion may affect other medications or be affected by them.
Some medications reduce the effect of Bridion
→It is especially important to inform your anesthesiologist if you have taken recently:
Bridion may affect hormonal contraceptives
→ If you are takingThe Pillon the same day that Bridion is administered, follow the instructions in case of missing a pill from the pill package.
→ If you are usingotherhormonal contraceptives (for example vaginal ring, implant, or IUD‑h), you should use a non-hormonal contraceptive method (such as a condom) for the next 7days and follow the package instructions.
Effects on blood tests
In general, Bridion has no effect on laboratory tests. However, it may affect the results of a blood test when measuring progesterone hormone levels. Consult your doctor if your progesterone levels need to be analyzed on the same day you receive Bridion.
Pregnancy and breastfeeding
→Inform your anesthesiologist if you are pregnant or may be pregnant or if you are breastfeeding.
It is possible that Bridion will still be administered, but it is necessary to discuss it first.
No information is available on whether sugammadex can pass into breast milk. Your anesthesiologist will help you decide whether to stop breastfeeding or avoid sugammadex treatment, considering the benefits of breastfeeding for the baby and the benefits of Bridion for the mother.
Driving and operating machinery
Bridion has no known influence on the ability to drive and operate machinery.
Bridion contains sodium
This medication contains up to 9.7mg of sodium (main component of table salt/for cooking) in each ml. This is equivalent to 0.5% of the maximum daily sodium intake recommended for an adult.
Bridion will be administered by your anesthesiologist, or under the supervision of your anesthesiologist.
Dose
Your anesthesiologist will calculate the dose of Bridion that you need based on:
The usual dose is 2-4 mg per kg of body weight for adults and for children and adolescents between 2-17 years old. A dose of 16 mg/kg may be used in adults if urgent recovery of muscle relaxation is needed.
How Bridion is Administered
Bridion will be administered by your anesthesiologist. It is given as a single intravenous injection.
If More Bridion is Injected than Recommended
Since your anesthesiologist will be closely monitoring the situation, it is unlikely that too much Bridion will be administered. Even if this happens, it is unlikely to cause any problems.
If you have any other questions about the use of this medication, ask your anesthesiologist or another doctor.
Like all medicines, this medicine may cause side effects, although not everyone will experience them.
If these side effects occur while you are under the effects of anesthesia, your anesthesiologist will detect and treat them.
Frequent (may affect up to 1 in 10 people)
Possibly frequent (may affect up to 1 in 100 people)
Unknown frequency
Reporting of side effects
If you experience any type of side effect, consult your anesthesiologist or another doctor, even if it is a possible side effect not listed in this prospectus. You can also report them directly through theNational Reporting System included in theAppendix V. By reporting side effects, you can contribute to providing more information about the safety of this medicine.
Storage will be handled by healthcare professionals.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the box and on the label after “CAD”. The expiration date is the last day of the month indicated.
Store below 30°C. Do not freeze. Store the vial in the outer packaging to protect it from light.
Once opened and diluted, store at 2‑8°C and use within 24 hours.
Composition of Bridion
Each milliliter of injectable solution contains sugammadex sodium equivalent to 100mg of sugammadex.
Each vial of 2ml contains sugammadex sodium equivalent to 200mg of sugammadex.
Each vial of 5ml contains sugammadex sodium equivalent to 500mg of sugammadex.
Appearance of the product and contents of the package
Bridion is a transparent, colorless to slightly yellowish injectable solution.
It is presented in two different package sizes, 10vials of 2ml or 10vials of 5ml of injectable solution.
Only some package sizes may be commercially available.
Holder of the marketing authorization Merck Sharp & Dohme B.V. Waarderweg39 2031BN Haarlem Netherlands | Responsible for manufacturing N.V. Organon Kloosterstraat6 5349AB Oss Netherlands Merck Sharp & Dohme B.V. Waarderweg39 2031BN Haarlem Netherlands |
For more information about this medicinal product, please contact the local representative of the marketing authorization holder:
Belgium/Belgique/Belgien MSD Belgium Tel/Tél: +32(0)27766211 | Lithuania UAB Merck Sharp & Dohme Tel: +370 5 278 02 47 |
Bulgaria Merck Sharp & Dohme EOOD Tel: +359 2 819 3737 | Luxembourg/Luxemburg MSD Belgium Tel/Tél: +32(0)27766211 |
Czech Republic Merck Sharp & Dohme s.r.o. Tel.: +420 233 010 111 | Hungary MSD Pharma Hungary Kft. Tel.: +36 1 888 5300 |
Denmark MSD Danmark ApS Tlf: +45 4482 4000 | Malta Merck Sharp & Dohme Cyprus Limited Tel: 8007 4433 (+356 99917558) |
Germany Grünenthal GmbH Tel: +49 (0) 241 569 1111 | Netherlands Merck Sharp & Dohme B.V. Tel.: 0800 9999000 (+31 23 5153153) |
Estonia Merck Sharp & Dohme OÜ Tel: + 372 6144 200 | Norway MSD (Norge) AS Tlf: +47 32 20 73 00 |
Greece MSD Α.Φ.Β.Ε.Ε. Tel: +30 210 98 97 300 | Austria Merck Sharp & Dohme Ges.m.b.H. Tel: +43 (0) 1 26 044 |
Spain Merck Sharp & Dohme de España, S.A. Tel: +34 91 321 06 00 | Poland MSD Polska Sp. z o.o. Tel.: +48 22 549 51 00 |
France MSD France Tél: + 33-(0)1 80 46 40 40 | Portugal Merck Sharp & Dohme, Lda Tel: +351 21 446 57 00 |
Croatia Merck Sharp & Dohme d.o.o. Tel: + 385 1 6611 333 | Romania Merck Sharp & Dohme Romania S.R.L. Tel: +40 21 529 29 00 |
Ireland Merck Sharp and Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 | Slovenia Merck Sharp & Dohme, inovativna zdravila d.o.o. Tel: +386 1 5204201 |
Iceland Vistor hf. Tel: +354 535 7000 | Slovakia Merck Sharp & Dohme, s. r. o. Tel: +421 2 58282010 |
Italy MSD Italia S.r.l. Tel: 800 23 99 89 (+39 06 361911) | Finland MSD Finland Oy Tel: +358 (0) 9 804650 |
Cyprus Merck Sharp & Dohme Cyprus Limited Tel: 800 00 673 (+357 22866700) | Sweden Merck Sharp & Dohme (Sweden) AB Tel: +46 77 5700488 |
Lithuania SIA Merck Sharp & Dohme Latvija Tel: +371 67 364224 | United Kingdom (Northern Ireland) Merck Sharp & Dohme Ireland (Human Health) Limited Tel: +353 (0)1 2998700 |
Last update of this leaflet:<{MM/AAAA}><{month YYYY}>.
For detailed information on this medicinal product, please visit the website of the European Medicines Agency:http://www.ema.europa.eu.
--------------------------------------------------------------------------------------------------------------------------
This information is intended for healthcare professionals only:
For detailed information, please refer to the SmPC or the Product Information of BRIDION.
Have questions about this medication or your symptoms? Connect with a licensed doctor for guidance and personalized care.